Dual antibody B

Phase 2Small molecule

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Dual antibody B is one of 60 small molecule programs targeting Atrial Fibrillation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial FibrillationActive, not recruiting

Adjuvant TherapyRecruiting

Atrial FibrillationPreclinical

Active, not recruiting

Adjuvant TherapyPhase 2

Recruiting

Competition

Competitive Landscape

137 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Calquence

AstraZeneca

Preclinical

1 2

Rituxan

Coumadin

3 4

Dual antibody B

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2

1 5

Brukinsa

BBeOne Medicines

Preclinical

1 6

Imbruvica

PPharmacyclics LLC.

Preclinical

1 7

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 8

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 9

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Adjuvant Therapy

NCT06936046

Clinical

Trials by Indication[1]

Adjuvant Therapy1 trial

Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06936046·200 enrolled

Atrial Fibrillation1 trial

Exploratory Observation of Two Short-term Regimens After LAA Occlusion by LAMax LAAC® Device for Subjects With Non-valvular Atrial Fibrillation

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05761704·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dual antibody B. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dual antibody B compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dual antibody B. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Dual antibody B

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Adjuvant Therapy1 trial

Atrial Fibrillation1 trial

References

Drug Info

Quick Facts

Related News